Ionis Pharmaceuticals Inc (NASDAQ:IONS) Chairman Stanley T. Crooke sold 22,000 shares of the company’s stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $50.01, for a total transaction of $1,100,220.00. Following the completion of the sale, the chairman now directly owns 58,014 shares in the company, valued at $2,901,280.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Ionis Pharmaceuticals Inc (NASDAQ:IONS) traded down $0.54 during trading on Friday, reaching $49.48. 1,067,600 shares of the company’s stock were exchanged, compared to its average volume of 1,050,267. The firm has a market cap of $6,200.00, a price-to-earnings ratio of 353.43 and a beta of 2.86. Ionis Pharmaceuticals Inc has a 12 month low of $37.26 and a 12 month high of $65.51. The company has a debt-to-equity ratio of 1.50, a quick ratio of 6.21 and a current ratio of 6.25.
A number of institutional investors have recently added to or reduced their stakes in IONS. Russell Investments Group Ltd. lifted its holdings in Ionis Pharmaceuticals by 21.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 20,077 shares of the company’s stock worth $1,021,000 after buying an additional 3,538 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in Ionis Pharmaceuticals by 17.4% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 367,550 shares of the company’s stock worth $18,698,000 after buying an additional 54,587 shares in the last quarter. SG Americas Securities LLC lifted its holdings in Ionis Pharmaceuticals by 30.9% during the 2nd quarter. SG Americas Securities LLC now owns 6,315 shares of the company’s stock worth $321,000 after buying an additional 1,489 shares in the last quarter. Legal & General Group Plc lifted its holdings in Ionis Pharmaceuticals by 9.7% during the 2nd quarter. Legal & General Group Plc now owns 44,480 shares of the company’s stock worth $2,262,000 after buying an additional 3,944 shares in the last quarter. Finally, BNP Paribas Arbitrage SA lifted its holdings in Ionis Pharmaceuticals by 29.7% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 17,252 shares of the company’s stock worth $878,000 after buying an additional 3,946 shares in the last quarter. Institutional investors own 91.40% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Ionis Pharmaceuticals Inc (IONS) Chairman Sells $1,100,220.00 in Stock” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/05/ionis-pharmaceuticals-inc-ions-chairman-sells-1100220-00-in-stock.html.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.